PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
24025252-8	2013	(4) PP2A activity is known to be regulated by the bioactive lipid ceramide, and this occurs through both I2PP2A inhibition and PP2A de-repression and through ceramide actions on subunits of the PP2A enzyme complex.	Ceramides	66-74	SET nuclear proto-oncogene	Homo sapiens	105-111
24025252-10	2013	They determined whether ceramide could decrease accumulation of the oncogene c-Myc through inhibition of I2PP2A and activation of PP2A.	Ceramides	24-32	SET nuclear proto-oncogene	Homo sapiens	105-111
24025252-11	2013	As I2PP2A is also an inhibitor of histone acetylation they determined whether ceramide could block the epigenetic action of I2PP2A.	Ceramides	78-86	SET nuclear proto-oncogene	Homo sapiens	124-130
24025258-3	2013	We have investigated the effect of the small chain C6-ceramide, known to be a bioactive tumor suppressor lipid, on I2PP2A function, thereby affecting c-Myc signaling and histone acetylation in cells.	N-caproylsphingosine	51-62	SET nuclear proto-oncogene	Homo sapiens	115-121
24025258-5	2013	C6-ceramide was able to disrupt the association between PP2A and I2PP2A.	N-caproylsphingosine	0-11	SET nuclear proto-oncogene	Homo sapiens	65-71
24025258-6	2013	C6-ceramide inhibits I2PP2A"s upregulation of c-Myc and downregulation of histone acetylation in prostate cancer cells.	N-caproylsphingosine	0-11	SET nuclear proto-oncogene	Homo sapiens	21-27
24025258-7	2013	Our data indicated that targeting cancer related signaling pathways through I2PP2A using ceramide as an anti-I2PP2A agent could have beneficial effects as a therapeutic approach to prevent prostate cancer.	Ceramides	89-97	SET nuclear proto-oncogene	Homo sapiens	76-82
24025258-7	2013	Our data indicated that targeting cancer related signaling pathways through I2PP2A using ceramide as an anti-I2PP2A agent could have beneficial effects as a therapeutic approach to prevent prostate cancer.	Ceramides	89-97	SET nuclear proto-oncogene	Homo sapiens	109-115
22245669-0	2012	Lentivirus-mediated silencing of I2PP2A through RNA interference attenuates trichloroethylene-induced cytotoxicity in human hepatic L-02 cells.	Trichloroethylene	76-93	SET nuclear proto-oncogene	Homo sapiens	33-39
23180565-2	2013	We show here that the tumour suppressor ceramide binds I2PP2A/SET selectively in the nucleus and including its K209 and Y122 residues as determined by molecular modelling/simulations and site-directed mutagenesis.	Ceramides	40-48	SET nuclear proto-oncogene	Homo sapiens	55-61
23180565-3	2013	Because I2PP2A/SET was found overexpressed, whereas ceramide was downregulated in lung tumours, a sphingolipid analogue drug, FTY720, was identified to mimick ceramide for binding and targeting I2PP2A/SET, leading to PP2A reactivation, lung cancer cell death, and tumour suppression in vivo.	Sphingolipids	98-110	SET nuclear proto-oncogene	Homo sapiens	8-14
23180565-3	2013	Because I2PP2A/SET was found overexpressed, whereas ceramide was downregulated in lung tumours, a sphingolipid analogue drug, FTY720, was identified to mimick ceramide for binding and targeting I2PP2A/SET, leading to PP2A reactivation, lung cancer cell death, and tumour suppression in vivo.	Sphingolipids	98-110	SET nuclear proto-oncogene	Homo sapiens	194-200
23180565-3	2013	Because I2PP2A/SET was found overexpressed, whereas ceramide was downregulated in lung tumours, a sphingolipid analogue drug, FTY720, was identified to mimick ceramide for binding and targeting I2PP2A/SET, leading to PP2A reactivation, lung cancer cell death, and tumour suppression in vivo.	Ceramides	159-167	SET nuclear proto-oncogene	Homo sapiens	8-14
23180565-3	2013	Because I2PP2A/SET was found overexpressed, whereas ceramide was downregulated in lung tumours, a sphingolipid analogue drug, FTY720, was identified to mimick ceramide for binding and targeting I2PP2A/SET, leading to PP2A reactivation, lung cancer cell death, and tumour suppression in vivo.	Ceramides	159-167	SET nuclear proto-oncogene	Homo sapiens	194-200
22673740-7	2012	PP2A can be directly activated by ceramide and SET/I2PP2A can be inhibited by ceramide.	Ceramides	78-86	SET nuclear proto-oncogene	Homo sapiens	51-57
23180565-0	2013	Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.	Sphingosine	0-11	SET nuclear proto-oncogene	Homo sapiens	41-47
22245669-3	2012	In a previous proteomics study, we found that TCE exposure up-regulated the expression of the inhibitor 2 of protein phosphatase 2A (I2PP2A), a potent and specific endogenous inhibitor of protein phosphatase (PP) 2A, in human hepatic L-02 cells.	Trichloroethylene	46-49	SET nuclear proto-oncogene	Homo sapiens	94-131
22245669-3	2012	In a previous proteomics study, we found that TCE exposure up-regulated the expression of the inhibitor 2 of protein phosphatase 2A (I2PP2A), a potent and specific endogenous inhibitor of protein phosphatase (PP) 2A, in human hepatic L-02 cells.	Trichloroethylene	46-49	SET nuclear proto-oncogene	Homo sapiens	133-139
22245669-5	2012	We found that TCE treatment of L-02 cells causes decreased cell viability, increased apoptosis and elevated I2PP2A mRNA and protein levels.	Trichloroethylene	14-17	SET nuclear proto-oncogene	Homo sapiens	108-114
22245669-7	2012	Lentivirus-mediated I2PP2A knockdown partially prevented the decrease in viability and increased apoptosis induced by TCE treatment.	Trichloroethylene	118-121	SET nuclear proto-oncogene	Homo sapiens	20-26
22245669-8	2012	Knockdown of I2PP2A in TCE-treated L-02 cells also suppressed the inhibition of PP2A activity and prevented caspase-3 activation.	Trichloroethylene	23-26	SET nuclear proto-oncogene	Homo sapiens	13-19
22245669-9	2012	These data for the first time demonstrate that the up-regulation of I2PP2A could mediate, at least in part, TCE-induced liver cell toxicity through the inhibition of PP2A activity and caspase-3-mediated pathway, and suggest that I2PP2A may play a crucial role in mediating TCE hepatotoxicity.	Trichloroethylene	108-111	SET nuclear proto-oncogene	Homo sapiens	68-74
22245669-9	2012	These data for the first time demonstrate that the up-regulation of I2PP2A could mediate, at least in part, TCE-induced liver cell toxicity through the inhibition of PP2A activity and caspase-3-mediated pathway, and suggest that I2PP2A may play a crucial role in mediating TCE hepatotoxicity.	Trichloroethylene	108-111	SET nuclear proto-oncogene	Homo sapiens	229-235
22245669-9	2012	These data for the first time demonstrate that the up-regulation of I2PP2A could mediate, at least in part, TCE-induced liver cell toxicity through the inhibition of PP2A activity and caspase-3-mediated pathway, and suggest that I2PP2A may play a crucial role in mediating TCE hepatotoxicity.	Trichloroethylene	273-276	SET nuclear proto-oncogene	Homo sapiens	68-74
22245669-9	2012	These data for the first time demonstrate that the up-regulation of I2PP2A could mediate, at least in part, TCE-induced liver cell toxicity through the inhibition of PP2A activity and caspase-3-mediated pathway, and suggest that I2PP2A may play a crucial role in mediating TCE hepatotoxicity.	Trichloroethylene	273-276	SET nuclear proto-oncogene	Homo sapiens	229-235
22216318-4	2011	Two host proteins, B23 and I2PP2A, were found to interact preferentially with the alanine-substituted CTD.	Alanine	82-89	SET nuclear proto-oncogene	Homo sapiens	27-33
21419339-4	2011	Mechanistically, PI3Kgamma inhibits PP2A activity at the betaAR complex by phosphorylating an intracellular inhibitor of PP2A (I2PP2A) on serine residues 9 and 93, resulting in enhanced binding to PP2A.	Serine	138-144	SET nuclear proto-oncogene	Homo sapiens	127-133
21419339-5	2011	Indeed, enhanced phosphorylation of beta2ARs is observed with a phosphomimetic I2PP2A mutant that was completely reversed with a mutant mimicking dephosphorylated state.	beta2ars	36-44	SET nuclear proto-oncogene	Homo sapiens	79-85
22216318-4	2011	Two host proteins, B23 and I2PP2A, were found to interact preferentially with the alanine-substituted CTD.	3-deazacytidine	102-105	SET nuclear proto-oncogene	Homo sapiens	27-33
20140906-5	2010	In samples incubated with S(-) and R(+) warfarin alone, the multi-task protein Protein SET showed significant elevation in cells incubated with S(-) warfarin but not in those incubated with R(+) warfarin.	Warfarin	40-48	SET nuclear proto-oncogene	Homo sapiens	79-90
20140906-5	2010	In samples incubated with S(-) and R(+) warfarin alone, the multi-task protein Protein SET showed significant elevation in cells incubated with S(-) warfarin but not in those incubated with R(+) warfarin.	Warfarin	149-157	SET nuclear proto-oncogene	Homo sapiens	79-90
20140906-5	2010	In samples incubated with S(-) and R(+) warfarin alone, the multi-task protein Protein SET showed significant elevation in cells incubated with S(-) warfarin but not in those incubated with R(+) warfarin.	Warfarin	149-157	SET nuclear proto-oncogene	Homo sapiens	79-90
18931446-0	2008	Effect of leucine-to-methionine substitutions on the diffraction quality of histone chaperone SET/TAF-Ibeta/INHAT crystals.	Leucine	10-17	SET nuclear proto-oncogene	Homo sapiens	98-107
19028839-1	2009	In this study, the inhibitor 2 of protein phosphatase 2A (I2PP2A) was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference.	Ceramides	107-115	SET nuclear proto-oncogene	Homo sapiens	19-56
19028839-1	2009	In this study, the inhibitor 2 of protein phosphatase 2A (I2PP2A) was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference.	Ceramides	107-115	SET nuclear proto-oncogene	Homo sapiens	58-64
19028839-1	2009	In this study, the inhibitor 2 of protein phosphatase 2A (I2PP2A) was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference.	Fatty Acids	177-187	SET nuclear proto-oncogene	Homo sapiens	19-56
19028839-1	2009	In this study, the inhibitor 2 of protein phosphatase 2A (I2PP2A) was identified in vitro and in situ as a ceramide-binding protein, which exhibits stereoisomer specificity and fatty acid chain length preference.	Fatty Acids	177-187	SET nuclear proto-oncogene	Homo sapiens	58-64
19028839-2	2009	Site- directed mutagenesis coupled with structural details of I2PP2A suggested that VIK 207-209 residues localized on helix 7 are important for ceramide binding and single mutation of K209D altered this interaction.	Ceramides	144-152	SET nuclear proto-oncogene	Homo sapiens	62-68
19028839-5	2009	Importantly, whereas down-regulation of I2PP2A enhanced PP2A-mediated c-Myc degradation in response to ceramide, ectopic expression of wild-type I2PP2A but not of its K209D mutant protected this degradation in A549 cells.	Ceramides	103-111	SET nuclear proto-oncogene	Homo sapiens	40-46
19028839-6	2009	Moreover, expression of wild-type I2PP2A prevented the growth-inhibitory effects of ceramide both against A549 cells and xenograft-driven tumors in situ and in vivo compared with that in controls.	Ceramides	84-92	SET nuclear proto-oncogene	Homo sapiens	34-40
19028839-7	2009	Thus, these results suggest that direct interaction of I2PP2A with ceramide plays important biological roles via the regulation of PP2A activity and signaling, which in turn control ceramide-mediated degradation of c-Myc and antiproliferation.	Ceramides	67-75	SET nuclear proto-oncogene	Homo sapiens	55-61
19028839-7	2009	Thus, these results suggest that direct interaction of I2PP2A with ceramide plays important biological roles via the regulation of PP2A activity and signaling, which in turn control ceramide-mediated degradation of c-Myc and antiproliferation.	Ceramides	182-190	SET nuclear proto-oncogene	Homo sapiens	55-61
18931446-0	2008	Effect of leucine-to-methionine substitutions on the diffraction quality of histone chaperone SET/TAF-Ibeta/INHAT crystals.	Methionine	21-31	SET nuclear proto-oncogene	Homo sapiens	98-107
15632079-3	2005	TAF-I associates with chromatin in vitro and can substitute for the related protein NAP-1 in assembling chromatin onto cloned DNA templates in cooperation with the remodeling enzyme ATP-dependent chromatin assembly factor (ACF).	Adenosine Triphosphate	182-185	SET nuclear proto-oncogene	Homo sapiens	0-5
16388607-4	2006	We found that a major binding region of pre-VII with both DNA and the acidic carboxyl-terminal region of TAF-I lies in the arginine-rich region of pre-VII.	Arginine	123-131	SET nuclear proto-oncogene	Homo sapiens	105-110
16388607-6	2006	A TAF-I mutant protein lacking the acidic carboxyl-terminal region bound preferentially to the carboxyl-terminal region of pre-VII containing the arginine-rich region rather than the amino-terminal region of pre-VII.	Arginine	146-154	SET nuclear proto-oncogene	Homo sapiens	2-7
10490631-5	1999	Human TAF-Ibeta has a chromatin decondensation activity comparable to that of NAP-I, another histone binding protein, whereas TAF-Ialpha has only a weak activity.	nap-i	78-83	SET nuclear proto-oncogene	Homo sapiens	6-15
12819770-3	2003	Limited proteolysis of a high-molecular-mass complex containing SET (also named putative HLA-associated protein II or PHAPII), PHAPI (pp32, leucine-rich acidic nuclear protein) and HMG2 by GzmA liberates NM23-H1, a Mg2+-dependent DNase that causes single-stranded breaks in nuclear DNA.	magnesium ion	215-219	SET nuclear proto-oncogene	Homo sapiens	118-124
9256474-7	1997	PHAP II forms an SDS-stable complex with recombinant mutant granzyme A and coprecipitates with it from cytoplasmic extracts.	Sodium Dodecyl Sulfate	17-20	SET nuclear proto-oncogene	Homo sapiens	0-7
28977641-7	2017	When PP32 and SET/TAF-Ibeta protein levels are down-regulated in vivo, we detect hyperacetylation on lysines 5 and 12 and other H4 lysine residues.	Lysine	101-107	SET nuclear proto-oncogene	Homo sapiens	18-27
8192856-3	1994	Here we report on two putative HLA class II associated proteins (PHAPI and PHAPII) which have been purified from the cytosolic fraction of the human lymphoblastoid B-cell line H2LCL using an affinity matrix composed of the synthetic biotinylated cytoplasmic region of the DR2 alpha chain immobilized on avidin agarose.	Sepharose	310-317	SET nuclear proto-oncogene	Homo sapiens	75-81
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	Ammonium Sulfate	136-152	SET nuclear proto-oncogene	Homo sapiens	92-97
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	phosphocellulose	195-211	SET nuclear proto-oncogene	Homo sapiens	62-90
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	phosphocellulose	195-211	SET nuclear proto-oncogene	Homo sapiens	92-97
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	q-sepharose	216-227	SET nuclear proto-oncogene	Homo sapiens	62-90
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	q-sepharose	216-227	SET nuclear proto-oncogene	Homo sapiens	92-97
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	Glycerol	233-241	SET nuclear proto-oncogene	Homo sapiens	62-90
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	Glycerol	233-241	SET nuclear proto-oncogene	Homo sapiens	92-97
34156643-0	2021	1HN, 13C, and 15N backbone resonance assignments of the SET/TAF-1beta/I2PP2A oncoprotein (residues 23-225).	1-Hydroxy-2-naphthoic acid	0-3	SET nuclear proto-oncogene	Homo sapiens	70-76
34489496-6	2021	TAF-I maintains the histone H3 modifications involved in transcriptional activation and hypomethylated cytosines in CpG dinucleotides around the transcription start site (TSS) in the TERT gene locus.	Cytosine	103-112	SET nuclear proto-oncogene	Homo sapiens	0-5
34489496-6	2021	TAF-I maintains the histone H3 modifications involved in transcriptional activation and hypomethylated cytosines in CpG dinucleotides around the transcription start site (TSS) in the TERT gene locus.	cytidylyl-3'-5'-guanosine	116-133	SET nuclear proto-oncogene	Homo sapiens	0-5
8486711-4	1993	The factor stimulating Ad core DNA replication, designated as template activating factor I (TAF-I), was purified by successive steps of ammonium sulfate precipitation, column chromatographies on phosphocellulose and Q-Sepharose, and glycerol density gradient centrifugation.	Ammonium Sulfate	136-152	SET nuclear proto-oncogene	Homo sapiens	62-90
31239152-6	2019	Therefore, we hypothesized that Ang II might attenuate I2PP2A expression to activate PP2A, which downregulates eNOS Ser 1177 phosphorylation, leading to eNOS dysfunction.	Serine	116-119	SET nuclear proto-oncogene	Homo sapiens	55-61
30453012-11	2019	A model of how CLN8 along with ceramides affects I2PP2A and PP2A binding and activities is proposed.	Ceramides	31-40	SET nuclear proto-oncogene	Homo sapiens	49-55
28977641-7	2017	When PP32 and SET/TAF-Ibeta protein levels are down-regulated in vivo, we detect hyperacetylation on lysines 5 and 12 and other H4 lysine residues.	Lysine	101-108	SET nuclear proto-oncogene	Homo sapiens	18-27
25050888-7	2014	Structural simulation model had also indicated that the direct binding of ceramide to inhibitor 2 of PP2A (I2PP2A) could reactivate PP2A and cause cell death.	Ceramides	74-82	SET nuclear proto-oncogene	Homo sapiens	107-113
27244888-0	2016	Isoliensinine induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction.	isoliensinine	0-13	SET nuclear proto-oncogene	Homo sapiens	161-167
25152123-1	2014	OBJECTIVE: To explore the effect of RNA interference of human I2PP2A gene on the proliferation and apoptosis of retinoic acid-resistant human acute promyelocytic leukemia (APL) cell line NB4-R1.	Tretinoin	112-125	SET nuclear proto-oncogene	Homo sapiens	62-68
25152123-2	2014	METHODS: Designed and constructed a RNA interference lentiviral vector I2PP2A-shRNA which targeted against I2PP2A gene, then transfected it into NB4-R1 via polybrene mediation.	Hexadimethrine Bromide	156-165	SET nuclear proto-oncogene	Homo sapiens	71-77
25152123-2	2014	METHODS: Designed and constructed a RNA interference lentiviral vector I2PP2A-shRNA which targeted against I2PP2A gene, then transfected it into NB4-R1 via polybrene mediation.	Hexadimethrine Bromide	156-165	SET nuclear proto-oncogene	Homo sapiens	107-113
24718855-10	2014	GLE also downregulated the expression of genes associated with invasive behavior (HRAS, VIL2, S100A4, MCAM, I2PP2A and FN1) in MDA-MB-231 cells.	GLE	0-3	SET nuclear proto-oncogene	Homo sapiens	108-114